Atkinson MH, Ménard HA, Kalish GH Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis. Clin Ther. 1995 Sep-Oct;17(5):827-37.
Barnes PJ, Karin M Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997 Apr 10;336(15):1066-71. Review.
Bleeker MW, Kooijman M, Rongen GA, Hopman MT, Smits P Preserved contribution of nitric oxide to baseline vascular tone in deconditioned human skeletal muscle. J Physiol. 2005 Jun 1;565(Pt 2):685-94. Epub 2005 Mar 31.
Bombardier C, Peloso PM, Goldsmith CH Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group. J Rheumatol. 1995 Apr;22(4):617-24.
Casaburi R Skeletal muscle function in COPD. Chest. 2000 May;117(5 Suppl 1):267S-71S. Review.
Eskurza I, Myerburgh LA, Kahn ZD, Seals DR Tetrahydrobiopterin augments endothelium-dependent dilatation in sedentary but not in habitually exercising older adults. J Physiol. 2005 Nov 1;568(Pt 3):1057-65. Epub 2005 Sep 1.
Fukai T Endothelial GTPCH in eNOS uncoupling and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1493-5.
Keatings VM, Collins PD, Scott DM, Barnes PJ Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996 Feb;153(2):530-4.
Mercier JG, Hokanson JF, Brooks GA Effects of cyclosporine A on skeletal muscle mitochondrial respiration and endurance time in rats. Am J Respir Crit Care Med. 1995 May;151(5):1532-6.
Plotnick GD, Corretti MC, Vogel RA Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 1997 Nov 26;278(20):1682-6.
Rubanyi GM, Vanhoutte PM Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 1986 May;250(5 Pt 2):H822-7.
Sander M, Chavoshan B, Victor RG A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension. 1999 Apr;33(4):937-42.
Schächinger V, Britten MB, Zeiher AM Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000 Apr 25;101(16):1899-906.
Selvaraj CL, Gurm HS, Gupta R, Ellis SG, Bhatt DL Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2005 Sep 15;96(6):756-9.
Shapiro SD, Senior RM Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol. 1999 Jun;20(6):1100-2. Review.
Yin MJ, Yamamoto Y, Gaynor RB The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998 Nov 5;396(6706):77-80.
Zarubina EG, Mishina EA, Osadchuk MA [The role of endothelial dysfunction in the pathogenesis of combined cardiopulmonary diseases]. Klin Med (Mosk). 2006;84(5):31-4. Russian.
Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.